Understanding Retroperitoneal Sarcoma
The retroperitoneum - the anatomical space behind the abdominal cavity, containing the kidneys, major vessels, and retroperitoneal fat - is the site of origin for the majority of retroperitoneal tumors. Soft tissue sarcomas arising here are rare (approximately 0.3 per 100,000 per year), but their size at presentation and proximity to vital structures make them among the most technically challenging of all solid cancers.
Most common histological subtypes:
- Well-differentiated / dedifferentiated liposarcoma (WDLPS/DDLPS): The most frequent retroperitoneal sarcoma subtype; often large at presentation; local recurrence is the dominant oncological challenge
- Leiomyosarcoma (LMS): Arises from smooth muscle, including the inferior vena cava; more aggressive systemic behaviour; metastasises to lung and liver
- Solitary fibrous tumour, synovial sarcoma, MPNST: Less common subtypes requiring histology-specific systemic therapy strategies
Why size and biology matter:
- Most RPS present as large tumours (>10 cm, often >20 cm) discovered as an abdominal mass or incidentally on imaging
- Palpable abdominal mass, vague abdominal pain, and symptoms from compression of adjacent organs (ureter, bowel, inferior vena cava) are common presentations
- Retroperitoneal location means no early warning symptoms - most patients have extensive disease at first diagnosis
Diagnosis pathway:
- CT chest-abdomen-pelvis with IV contrast defines size, compartmental extent, and vascular involvement
- MRI provides superior soft-tissue characterisation and is preferred for pelvic sarcomas
- PET-CT assesses metabolic activity and distant spread in high-grade tumors
- Core needle biopsy under CT guidance confirms histological subtype and grade - essential before any treatment decision; surgical biopsy should be avoided
Surgical Treatment: Complete En-Bloc Resection
Surgery is the only curative treatment for retroperitoneal sarcoma. The surgical goal is complete (R0) resection with wide negative margins - because local recurrence, not systemic spread, is the primary cause of death in most RPS subtypes.
Compartmental en-bloc resection:
- The modern surgical standard for WDLPS/DDLPS involves removing the tumor together with all adjacent anatomical compartments - including ipsilateral kidney, adrenal gland, psoas fascia, and portions of the colon, mesentery, or diaphragm - to reduce the risk of local recurrence
- This approach yields significantly better local recurrence-free survival versus simple shelling-out (peeling) of the tumour mass
- Organ preservation decisions (particularly kidney) are made using pre-operative CT volumetry and renal function assessment
Vascular involvement:
- Tumors involving or encasing the inferior vena cava (IVC), iliac veins, or aorta require collaboration with vascular surgery for reconstruction
- IVC resection and reconstruction with prosthetic graft is performed at our partner centers when necessary
- Pre-operative planning includes vascular surgery consultation if CT shows IVC or major vessel compression or invasion
Technical considerations for specific subtypes:
- WDLPS/DDLPS: Wide compartmental resection; recurrence-free survival directly linked to margin width rather than histological grade
- LMS of the IVC: Segmental IVC resection with or without graft reconstruction; prognosis depends on IVC level and margin status
- Pelvic sarcomas: May require combined abdominal-perineal approach; complex pelvic floor reconstruction; multidisciplinary team input from urology and colorectal surgery
Robotic-assisted resection:
- Selected cases with favourable anatomy benefit from robotic-assisted resection - particularly for pelvic sarcomas where the precision of robotic instruments improves access to narrow spaces
- Open midline laparotomy remains standard for the majority of large retroperitoneal tumors requiring compartmental clearance
Radiation Therapy, Chemotherapy & Surveillance
For most retroperitoneal sarcoma subtypes, surgery drives outcomes - but radiation and chemotherapy play important supporting roles in reducing local recurrence risk and managing advanced disease.
Pre-operative (neoadjuvant) radiation therapy:
- External beam radiotherapy administered before surgery reduces microscopic tumour cells at the surgical margin - particularly valuable for large DDLPS and other high-grade tumors
- Neoadjuvant RT treats tumour in its native position before surgery moves structures - allowing more precise targeting and smaller radiation fields
- 25 fractions are typically delivered over 5 weeks before the planned resection; a 4-6 week interval after RT allows tissue recovery before surgery
- Neoadjuvant RT can be administered at a center near your home before traveling to Turkey for surgery
Adjuvant radiation therapy:
- Post-operative RT is considered when surgical margins are close or positive (R1), particularly for high-grade tumors
- Intraoperative radiation therapy (IORT) - a single large dose delivered directly to the tumour bed at the time of surgery - is available at selected partner centers
Chemotherapy:
- Liposarcomas are relatively chemoresistant; chemotherapy is generally reserved for DDLPS or systemic disease
- LMS and synovial sarcomas are more chemosensitive; Doxorubicin - Ifosfamide is the standard first-line regimen
- Trabectedin and Pazopanib are used for refractory disease
Surveillance after resection:
- CT chest-abdomen-pelvis every 3-4 months for the first 2 years; every 6 months for Years 3-5
- Local recurrence is most common in Year 1-3; early detection allows re-resection in selected patients
- Written surveillance schedule provided in English with home-provider handover documentation at discharge